Nipogalin (Cefuroxime Sodium)

Cefuroxime sodium, the active ingredient in Nipogalin, is a second‑generation cephalosporin presented as an injectable solution for intramuscular and intravenous use. It treats a range of bacterial infections in adult and pediatric patients. GNH USA supplies Nipogalin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Cefuroxime sodium is employed to manage bacterial infections across several organ systems.

- Community‑acquired pneumonia: provides bactericidal activity against common respiratory pathogens. - Urinary tract infection: eliminates susceptible Gram‑negative and Gram‑positive organisms. - Skin and soft‑tissue infection: treats cellulitis, wound infections, and abscesses caused by susceptible bacteria. - Acute otitis media: resolves middle‑ear infections caused by streptococci and Haemophilus species. - Acute bacterial sinusitis: reduces sinus inflammation by targeting typical causative bacteria.

Cefuroxime sodium may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: occasional feeling of queasiness. - Injection site pain: transient discomfort at the site of administration. - Rash: non‑specific skin erythema. - Elevated liver enzymes: transient increase in hepatic transaminases. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: severe intestinal inflammation. - Hemolytic anemia: destruction of red blood cells. - Stevens‑Johnson syndrome: severe mucocutaneous reaction. - Neutropenia: marked reduction in neutrophil count. - Renal impairment: worsening kidney function in susceptible patients.

Cefuroxime sodium should be used with careful clinical assessment and monitoring.

- Allergy assessment: verify no known hypersensitivity to cephalosporins or penicillins. - Renal function: adjust dosing in patients with impaired kidney function. - Hepatic monitoring: observe liver function tests during prolonged therapy. - Pregnancy and lactation: use only if the potential benefit outweighs risk; consult obstetric guidance. - Concomitant antibiotics: avoid unnecessary combination therapy that may increase toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Cefuroxime sodium can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Probenecid: reduces renal excretion, increasing cefuroxime plasma levels and risk of toxicity. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may increase risk of nephrotoxicity. - Oral contraceptives: potential reduction in contraceptive effectiveness. - Aminoglycosides: additive nephrotoxic potential when used together. - Live vaccines: concurrent use may diminish vaccine efficacy.